Introduction
============

The 'histone code' is a well-established hypothesis describing the idea that specific patterns of post-translational modifications to histones act like a molecular 'code' recognized and used by non-histone proteins to regulate specific chromatin functions \[[@b1]\]. One modification that has received significant attention is that of histone acetylation. The enzymes that regulate this modification are described as lysine acetyltransferases or KATs \[[@b4]\], and histone deacetylases or HDACs ([Table 1](#tbl1){ref-type="table"}) \[[@b6]\]. Although originally the activities of these enzymes were thought to only occur on histones, it is now well established that these enzymes can also alter non-histone proteins \[[@b7]\]. Due to their conserved catalytic domain HDACs have been actively targeted as a therapeutic target \[[@b9]\].

###### 

Current classes of HDACs

  **Class**   **HDAC members associated with**   **References**
  ----------- ---------------------------------- ----------------
  I           HDAC1, HDAC2, HDAC3, HDAC8         \[[@b6]\]
  IIA         HDAC4, HDAC5, HDAC7, HDAC9         \[[@b359]\]
  IIB         HDAC6, HDAC10                      \[[@b360]\]
  III         SIRT 1--7                          \[[@b6]\]
  IV          HDAC11                             \[[@b360]\]

In the following sections we will describe the evidence emerging from *in vitro* (cell culture) and *in vivo* (animal models) studies which indicate the usefulness of agents targeting HDACs in the treatment of disease using models of cancer, diabetes and neu-rodegenerative disease, and finish by describing the current emerging data from human clinical trials supporting the use of these drugs in the treatment of these diseases.

HATs/HDACs and the pro-inflammatory environment
===============================================

Inflammation is a critical component that is increasingly being associated with cancer \[[@b11]\], diabetes \[[@b13]\] and neurodegener-ative disease \[[@b14]\].

Histone modifying enzymes such as histone deacetylases have been identified as critical regulators of pro-inflammatory cascades. One of the best-established mechanisms identified concerns the roles of these enzymes in the regulation of nuclear factor κB (NF-κB) activation, as summarized in [Fig. 1](#fig01){ref-type="fig"}. The NF-κB-Rel family consists of five subunits, but NF-κB typically consists of a heterodimeric protein comprising a p50 and a p65 (RelA) sub-unit. Early studies identified the lysine acetyltransferases KAT3B and KAT3A as key coactivators in regulating NF-κB driven gene expression \[[@b15]\]. These interactions were found to involve the RelA/p65 subunit. Another lysine acetyltransferase KAT13A was found to also potentiate NF-κB transactivation through interactions with the other subunit p50 \[[@b18]\]. Following the identification of interactions between NF-κB and lysine acetyltransferases it was subsequently shown that the RelA/p65 subunit could associate with HDAC1 and HDAC2 to repress expression of NF-κB regulated genes as well as to control the induced level of expression of these genes \[[@b19]\].

![Interplay of KATs and HDACs in the regulation of NF-κB.](jcmm0013-0826-f1){#fig01}

It has since been shown that the histone deacetylase Sirtuin 1 (SIRT1) regulates NF-κB transactivation by physically interacting with the RelA/p65 subunit of NF-κB and inhibiting transcription by deacetylating a critical lysine at position 310 \[[@b20]\]. Both in vitro and in vivo exposure to cigarette smoke causes dose- and time-dependent decrease in SIRT1 protein and deacetylase activity resulting in increased NF-κB dependent pro-inflammatory mediator release \[[@b21]\].

One of the critical regulators of NF-κB activation is IκB kinase-α (IKK-α), where NF-κB transcription requires IKK-α to phospho-rylate silencing mediator for retinoic acid and thyroid hormone receptor, which stimulates the exchange of corepressor for coac-tivator complexes. In the initial stage of NF-κB activation, following this phosphorylation event HDAC3 is displaced, and this allows KAT3B to acetylate RelA/p65 \[[@b22]\].

Daxx is another protein that has been shown to regulate NF-κB activation by binding to a region that includes the major sites of acetylation mediated by KAT3B/KAT3A \[[@b24]\]. However, it must be noted that Daxx has also been shown to directly associate with HDAC2 \[[@b25]\], and so may represent a mechanism by which KATs and HDACs compete for critical lysines on NF-κB subunits. In this regard, small ubiquitin-like modifier modification of KAT3A negatively modulates its transcriptional activity by recruiting a Daxx complex that contains HDAC2 \[[@b26]\].

Pro-inflammatory genes associated with NF-κB are inter-leukins (IL)-6 and IL-8 \[[@b27]\]. NF-κB has also been shown to utilize the lysine acetyltransferase activity of KAT3A/KAT3B to stimulate the transcription of these genes \[[@b30]\]. Recently, breast cancer metastasis suppressor 1 (BRMS1) has been shown to decrease the transactivation potential of RelA/p65 by promoting binding of HDAC1 to RelA/p65, where it deacetylates lysine K310 on RelA/p65, suppressing transcriptional activity \[[@b31]\].

For a full comprehensive review of the role of HATs and HDACs in the regulation of NF-κB the reader is directed to the recent review by Carine Van Lint and colleagues \[[@b32]\].

HATs/HDACs and endoplasmic reticulum (ER) stress
================================================

The ability of a cell to sense, respond to and circumvent stress is essential for maintaining homeostasis. There are many ways in which stress, either endogenous or exogenous, can be manifested in a cell; these include pathogenic infection, chemical insult, genetic mutation, nutrient deprivation and even normal differentiation. The process of mutant protein folding is particularly sensitive to such insults. As such for the cellular compartments in which mutant proteins are processed and folded, there are adaptive programs that enable both their detection and correction for more efficient processing \[[@b33]\].

The ER is a large cellular organelle comprising a network of interconnected, closed membrane-bound vesicles. It is the site of synthesis, folding and modification of secretory and cell-surface proteins and serves many essential functions, including the production of the components of cellular membranes, proteins, lipids and sterols \[[@b34]\]. Only correctly folded proteins are transported out of the ER while incompletely folded proteins are retained in the organelle to complete the folding process or to be targeted for destruction \[[@b35]\]. Due to the important roles of this organelle, its proper functioning is essential to cellular homeostasis. However, various conditions can interfere with the ER function leading to ER stress. Stress is the response of any system to perturbations of its normal state. Thus, ER stress can arise from a disturbance in protein folding which results in an accumulation of unfolded or misfolded proteins within the organelle \[[@b36]\]. During such disturbances, in order to carry out the correct folding of proteins, the ER has evolved as a specialized protein-folding machine with cellular mechanisms that promote proper folding of aberrant protein, thus preventing its aggregation. Therefore, when ER homeostasis is altered by misfolded proteins, the ER responds by inducing the expression of specific genes in an attempt to restore normal ER function to and maintain stability \[[@b37]\]. The principle mechanisms of conformational disorders contained within the four pillars of ER stress: (*i*) protein degradation, (*ii*) endoplasmic overload response (EOR), (*iii*) unfolded protein response (UPR) and (*iv*) cellular death pathway. This four-stage model of ER stress toxicity helps explain its role in the onset of clinical manifestations. Two ER stress-induced signal transduction pathways have been described: the UPR \[[@b38]\] and the EOR \[[@b39]\]. The function of these pathways is to adapt to the disturbance and attempt to reestablish normal ER function \[[@b40]\]. However, excessive or prolonged ER stress may overwhelm the cell and elicit the cell death programme or apoptosis \[[@b41]\].

ER stress has been implicated as a critical component in diabetes \[[@b42]\], neurodegeneration \[[@b43]\] and cancer \[[@b45]\].

The evidence linking HATs/HDACs to ER Stress is not as well established as that for inflammation, with most studies utilising histone deacetylase inhibitors (HDi). However, in a recent study in hepatocytes on Mallory body (cytokeratin aggresomes) formation, decreased lysine acetyltransferase and increased histone deacetylase activity was observed \[[@b46]\]. In a similar model of oxidative stress induced inclusion formation, treatment of cells with 4-phenylbutyrate was found to alleviate formation of these inclusions \[[@b47]\].

Direct physical evidence for the association of HATs and HDACs with critical regulatory elements within the ER stress pathway is emerging. CHOP (C/EBP homologous protein) an ER stress-inducible protein which plays a critical role in regulating programmed cell death in stressed cells has recently been shown to directly associate with the lysine acetyltransferase KAT3B, and inhibition of HDACs prevents the degradation of CHOP \[[@b48]\].

Using chromatin immunoprecipitation strategies, KAT3B has been shown to bind to the promoter for the GRP78/BiP a prosurvival ER chaperone gene under conditions of ER stress \[[@b49]\]. In similar studies examining the promoters of ER-stress responsive genes, histone H4 acetylation was observed to show a promoter-specific increase following induction of stress \[[@b50]\].

B lymphocyte-induced maturation protein-1 (BLIMP-1) has been shown to be associated with cellular stress and is rapidly up-regulated during the UPR in some cellular models \[[@b51]\]. Of interest though is that fact that this repressor protein has also been shown to directly associate with histone deacetylases to repress transcription \[[@b52]\], indicating that histone deacetylases may utilize BLIMP-1 to down-regulate important genes during ER stress.

Initial in vitro data emerged demonstrating the efficacy of the HDi 4-phenylbutyrate in relieving ER stress in cell line models of cystic fibrosis \[[@b53]\], and also the liver disease mutant α1-anti-trypsin Z (α1-ATZ) \[[@b54]\]. Since these initial observations several studies have shown that 4-phenylbutyrate may act as a chemical chaperone to relieve ER stress induced in models of ischaemia \[[@b55]\]. Similar data have emerged for models of cataract formation \[[@b57]\], Parkinson\'s disease \[[@b58]\], retinitis pigmentosa \[[@b59]\], glaucoma \[[@b60]\] and confirmation of its effects in cystic fibrosis \[[@b61]\]. 4-Phenybutyrate has also been shown to relieve the ER stress observed in diabetes, where it has been shown to reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes, by the restoration of systemic insulin sensitivity, resolution of fatty liver disease, and enhancement of insulin action in liver, muscle and adipose tissues \[[@b62]\]. In hepatocytes, ER stress in liver induced ischaemia is ameliorated by treatments with 4-phenylbutyrate \[[@b56]\]. This compound has also been shown to have profound effects in alleviating ER tress induced by oxidative stress in cultured hepatocytes and hepatoma cells \[[@b47]\], and preventing ER stress mediated aggregate formation in a model of hereditary haemochromatosis \[[@b63]\].

Another HDi, valproate/valproic acid (VPA), has also been shown to have potential in the treatment of ER stress. The first indications that this drug may be of use in the treatment of ER stress came from studies which showed that treatment of cells with valproate caused the up-regulation of the expression of GRP78/BiP, a key ER-mediated chaperone \[[@b64]\]. Follow-up studies subsequently confirmed that valproate could increase the expression of additional important ER stress proteins, GRP94 and cal-reticulin \[[@b65]\]. In the same model system it was subsequently shown that valproate protected against oxidative stress induced protein damage and had neuroprotective capability \[[@b68]\].

The potential role of histone deacetylase inhibitors in the treatment of cancer
===============================================================================

Non-small cell cancer (NSCLC)
-----------------------------

Aberrant epigenetic modifications are a frequent hallmark of cancer and include both DNA CpG methylation \[[@b71]\], and histone post-translational modifications \[[@b72]\]. In NSCLC, altered patterns of DNA CpG methylation \[[@b73]\] and histone modifications \[[@b74]\] are found. In one study, no direct association between polymorphisms in histone deacetylase genes and risk of developing lung cancer was found \[[@b75]\]. Strong evidence is emerging, however, linking HDACs and their activities to NSCLC pathogenesis and prognosis.

Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory condition of the lung frequently associated with a higher risk of developing lung cancer \[[@b76]\]. A link between histone deacetylase activities and COPD was identified when studies revealed that in lung tissue of patients with increasing clinical stages of COPD, graded reductions in HDAC activity, reduced levels of HDAC2 protein and lower mRNA levels for HDACs 2, 5 and 8 were observed \[[@b77]\]. The decreased levels of HDAC2 have also been observed in separate studies of the effects of cigarette smoking in patients with COPD \[[@b78]\]. Of note, in contrast, elevated levels of HDAC1 have been observed in higher stage (stage III or IV) NSCLC \[[@b80]\]. A more recent study has also observed high expression of all class I HDACs in lung \[[@b81]\]. Using antibody arrays, HDAC3 protein was found to be elevated HDAC3 in 92% of squamous cell carcinomas of the lung \[[@b82]\]. It has, however, also been observed that decreased levels of class II HDACs have poor prognosis in NSCLC \[[@b83]\]. Another histone deacetylase SIRT1 has also recently been shown to be down-regulated in patients with COPD \[[@b84]\]. Most recently aberrant histone post-translational modifications have been shown to have prognostic value in NSCLC \[[@b74]\].

Decreased expression of mSin3A, a member of a multiple component corepressor complex that contains histone deacetylases, has also been observed in NSCLC \[[@b85]\]. Metastasis-associated protein 1 (MTA-1) has recently been shown to be significantly elevated in NSCLC and is strongly associated with both invasiveness and metastasis \[[@b86]\]. As MTA-1 is known to associate with histone deacetylases \[[@b87]\], this would suggest that HDAC activity associated with MTA-1 is involved with NSCLC invasiveness and metastasis.

Mutations within the lysine acetyltransferase KAT3A have also been identified in a small subset of NSCLC \[[@b93]\]. The importance of lysine acetyltransferase activity in lung development has been shown in mouse studies, where HATs were shown to be highly expressed in the developing lung \[[@b94]\], and confirmation of their importance in lung development came from KAT3B knockout studies \[[@b97]\]. Evidence is also emerging that histone deacetylases play important roles in the developing lung. Recently a homeodomain protein (HOP), which in the cardiac system associates with HDAC2 to repress cardiac-specific genes, was observed to be present in airway epithelium along with HDAC2. HOP was shown to represses lung-specific gene expression in an HDAC-dependent manner, and loss of HOP expression *in vivo* resulted in defective type 2 pneumocyte development \[[@b98]\].

The data emerging clearly show that HDACs and their activities play important roles in lung, and may also be important in the development of lung disease. As such they may also prove to be important therapeutic targets.

### In vitro evidence for targeting HDACs in NSCLC

The potential for therapeutic targeting of HDACs in NSCLC has been extensively studied *in vitro* using HDi. Some of the earliest reports examining the effects of sodium butyrate on lung cell lines demonstrated both cell growth effects and altered DNA hyperme-thylation \[[@b99]\]. In a Lewis lung carcinoma cells study, sodium butyrate was found to enhance the lung-colonizing ability of these cells \[[@b101]\]. Despite having adverse effects on growth and lung colonization, a subsequent study found that sodium butyrate potentiated DNA radiation sensitivity.

In contrast to the data obtained in 1986, a later study on transformed human lung fibroblasts found a dose-dependent induction of apoptosis and reduction in cell numbers after exposure to sodium butyrate \[[@b102]\]. Sodium butyrate was also shown to greatly enhance the antiproliferative effect *in vitro* and *in vivo* of interferon-α (IFN-α) on several human lung adenocarcinoma cell lines \[[@b103]\].

With the development of more sophisticated HDi, multiple studies have set out to examine the potential of HDi either alone or as combinatorial agents for the treatment of NCSLC. One of the first such studies, examined the effect of trapoxin on lung cancer cells, and found significant cell cycle arrest and apoptosis following treatment \[[@b104]\]. Further evidence for the potential of HDi in the treatment of lung cancer came from studies using suberoylanilide hydroxamic acid, SAHA (vorinostat), which was found to have chemopreventative efficacy against a tobacco-specific carcinogen model of lung tumourigenesis \[[@b105]\], and has also been shown to have growth inhibitory activity against NSCLC cell lines \[[@b106]\].

Trichostatin A (TSA) is another HDi that has been extensively studied as a potential therapeutic agent in the treatment on NSCLC. When the response of this drug against four NSCLC cell lines was compared against a normal lung fibroblast tenfold greater growth inhibition was found in the cancer cells, along with significant up-regulation of p21 \[[@b107]\]. TSA was shown to increase the expression of RECK and attenuate matrix metalloproteinase expression in lung cancer cells indicating HDi may help to prevent lung cancer cell invasion \[[@b108]\]. Death-associated protein kinase (DAPK) is a pro-apoptotic serine/threonine kinase involved in apoptosis, which is frequently down-regulated in NSCLC, and TSA has been shown to restore expression of DAPK in several NSCLC cell lines \[[@b109]\]. Loss of E-cadherin expression in NSCLC is also associated with de-differentiation, invasion and metastasis. WNT7a has been shown to regulate E-cadherin expression *via* a β-catenin specific mechanism or via a positive feedback loop, and loss of expression of WNT7a is a frequent event in NSCLC. In NSCLC cells E-cadherin and WNT7a expression was restored following treatment of cells with TSA \[[@b110]\]. RhoB is a small GTPase that is frequently down-regulated in NSCLC, and trapoxin was shown to significantly up-regulate the expression of RhoB in NSCLC cells \[[@b111]\], a finding subsequently confirmed using TSA \[[@b112]\]. Apoptosis induced by TSA in NSCLC cells has been shown to be associated with inhibition of cyclooxygenase 2 \[[@b113]\]. At the same time HDAC inhibitors such as sodium butyrate, scriptaid, apicidin and oxamflatin have also been shown to up-regulate the expression of 15-hydroxyprostaglandin dehy-drogenase (15-PGDH), a potential cyclooxygenase-2 (COX-2) antagonist in a time and concentration dependent manner in NSCLC cells \[[@b114]\].

A study testing the HDi (SAHA, TSA and sodium butyrate) demonstrated that the apoptotic response seen in NSCLC cells in response to HDi occurs *via* induction of caspase-3 activity \[[@b115]\]. Critically, activation of the NF-κB pathway via tumour necrosis factor-α (TNF-a) has been shown to be abrogated in NSCLC cell lines by TSA by down-regulating the mRNA and protein of its cognate receptor \[[@b117]\].

Another HDi romidepsin (FK228, FR901228, depsipeptide) was shown to affect NSCLC cell line tumour growth \[[@b118]\], and affect matrix metalloproteinase (MMP) expression in a manner similar to that observed for TSA. When administered to NSCLC cell lines romidepsin significantly decreased the expression of MMP-2 and MMP-9 in cells \[[@b119]\]. Treatment of NSCLC cells with romidepsin has also been shown to result in increased p21 and phosphorylated retinoblastoma protein (pRb) \[[@b120]\]. NVP-LAQ824 is another histone deacetylase that has been shown to inhibit cellular proliferation in lung cancer cells \[[@b121]\]. The oral histone deacetylase compound CI-994 (N-acetyldinaline) has also been studied in NSCLC cell lines, and found to have cytostatic properties \[[@b122]\]. Another synthetic HDi (SK-7041) has now been shown to have cell growth inhibitory properties greater than SAHA (vorinostat) in human lung cancer cell lines with lesser effects on normal human bronchial epithelial cells \[[@b123]\].

### Combinatorial therapies involving HDi in NSCLC

Synergy between inhibitors of DNA methyltransferases and histone deacetylases in the re-expression of genes silenced in colorectal cancer cell lines was established in 1989 \[[@b124]\]. Similar studies demonstrated the same synergies between Hdi and DNA methyl-transferase inhibitors in NSCLC cell lines \[[@b125]\], and also have been found to suppress tumorigenicity in NSCLC xenograft models but only when the tumours were small, and did not affect large well-established tumours. This may have important consequences for the use of HDi within the clinical setting \[[@b128]\]. Combined treatment using the HDi 4-phenylbutyrate and the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine, was shown to prevent tobacco carcinogen-induced lung cancer in wild-type mice \[[@b129]\].

A retinoid compound with the properties of retinoic acid (RA) and sodium butyrate (HDi) called (4-BPRE) was found to have greater cytotoxicity in A549 lung adenocarcinoma cells that RA alone indicating that this might be a good dual therapy for the treatment of NSCLC \[[@b130]\]. A further combinatorial treatment, which appears to have efficacy in NSCLC lung cancer cell lines, is a combination of a proteasome inhibitor (bortezomib) and an HDi. Initial studies using sodium butyrate as the HDi found that this combination could increase apoptosis 3- to 4- fold in NSCLC cell lines \[[@b131]\]. A follow up study using SAHA/vorinostat as the HDi, demonstrated that the increased efficacy of this combination (botezomib/SAHA) was due to a synergistic increase in reactive oxygen species \[[@b132]\].

Using a compound that targets the activation of the NF-κB pathway has also been examined in combination with the HDi SAHA. In this study it was found that the combination of these two compounds significantly induced more apoptosis and cell death than either drug alone \[[@b133]\], while a combination of a protein kinase C inhibitor (calphostin C) and a HDI (TSA) found that approximately 90% to 96% of NSCLC cells under-went apoptosis after exposure to this combination \[[@b134]\].

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is another compound that initially showed promise as a potential treatment for cancer. However, it has proven ineffective at inducing cell death when applied as a single agent. In one study, A549 lung carcinoma cells co-exposed to TRAIL and SAHA, sodium butyrate or TSA underwent substantial apoptosis \[[@b135]\]. VPA is another compound which also has HDi activity and a combination of this and TRAIL resulted in increased sensitization of cultured NSCLC cells to Apo2L/TRAIL, resulting in a 4- to \>20-fold reduction of Apo2L/TRAIL IC50 values in combination-treated cells. As stand alone agents, VPA or Apo2L/TRAIL induced less than 20% cell death, whereas in combination they caused 60% to 90% apoptosis of NSCLC cells.

Using a combination of SAHA and gemcitabine in NSCLC cell lines sequential treatment offered no improvement over concurrent treatment, whereas combined treatment showed enhanced apoptosis \[[@b136]\]. Similar results have also been observed for a combination utilising phenylbutyrate \[[@b137]\].

The efficacy of a combination of HDi (sodium butyrate) and a phosphatidylinositol 3-kinase/Akt inhibitor (LY294002) in NSCLC has also been demonstrated both *in vitro* and *in vivo*, where it was found that this combination was tumoristatic \[[@b138]\]. Similar results were observed when using a combination of a multiple receptor tyrosine kinase inhibitor AEE788 and HDi. When NSCLC cells were treated with AEE788 and HDAC inhibitors (LBH589, NVP-LAQ824 and TSA) in combination synergistic induction of apoptosis was observed which correlated with increased reactive oxygen species accumulation \[[@b139]\]. Similar studies using Romidepsin in combination with the kinase inhibitors AG1478, AG825, PD98059 and LY294002 found markedly enhanced FK228-induced apoptosis in NSCLC cells \[[@b140]\]. Romidepsin was also found to enhance the antitumour effects of an adenoviral telomerase-specific replication-selective agent (OBP-301) on NSCLC cell lines \[[@b141]\].

The bombesin/gastrin-releasing peptide receptor antagonist PD176252 was found to have enhanced inhibitory activity in lung cancer cell lines when combined with the HDi MS-275 \[[@b142]\].

Increased radiation sensitivity has been observed for a novel HDi (LBH589) targeting the classes I and II HDACs. Clonogenic survival showed that there was a greater than additive effect when LBH589 was administered prior to irradiation compared with irradiation alone. Subsequent *in vivo* tumour volume studies showed a growth delay of 20 days with combined treatment compared with 4 (radiation) and 2 days (LBH589) \[[@b143]\]. A similar increase in radiation sensitivity has also been observed in lung cancer cells treated with the HDi (NVP-LAQ824) \[[@b144]\].

Activating mutations of the epidermal growth factor receptor (EGFR) play critical roles in NSCLC survival, and have led to the development of targeted therapies \[[@b145]\]. A study examining a combination of the EGFR tyrosine kinase inhibitor erlotinib in combination with the HDi LBH589 found synergistic effects on lung cancer cells dependent on EGFR for growth and/or survival, and triggered apoptosis only in lung cancer cells which harboured EGFR mutations indicating that HDi treatments in NSCLC may prove to be of benefit to those patients which harbour EGFR mutations \[[@b146]\].

Another combinatorial treatment which shows efficacy in NSCLC cell lines involves TSA and etoposide, where co-treatment with these drugs induced apoptotic cell death in drug-resistant NSCLC cells, extending the notion that HDAC inhibitors in combination with conventional chemotherapeutic drugs could be a valuable therapeutic option in the treatment of NSCLC cancer \[[@b147]\].

Finally, a combination of an anti-inflammatory drug Sulindac, and SAHA has been shown to significantly enhance growth suppression and apoptosis in a NSCLC cell line, primarily through an enhancement of mitochondrial membrane potential collapse, release of cytochrome c and caspase activation \[[@b148]\].

Hepatocellular carcinoma (HCC)
------------------------------

Another cancer for which strong evidence exists linking the activities of lysine acetyltransferases and histone deacetylases to disease is HCC. In agreement with NSCLC, altered patterns of both DNA CpG methylation \[[@b149]\], and histone modifications \[[@b150]\] have also been observed in HCC.

We initially described the overexpression of histone deacetylases in the paediatric liver tumour hepatoblastoma \[[@b151]\]. Recent studies have shown that in patients with HCC high expression of HDAC1 was correlated with a higher incidence of cancer cell invasion into the portal vein, a poorer histological differentiation, a more advanced tumour node metastasis stage and had poorer prognosis \[[@b152]\]. In a gene microarray analysis of HCCs poor prognosis was observed for a subset of patients, which had elevated levels of various histone, modifying enzymes including HDAC2 \[[@b153]\]. Further evidence for the importance of histone deacetylases in the liver comes from transgenic mice overex-pressing HDAC1. These mice exhibit a high incidence of hepatic steatosis \[[@b154]\]. As non-alcoholic steatohepatitis frequently develop HCC \[[@b155]\], this would indicate that overexpression of HDAC expression may play a critical role in HCC pathogenesis. Other histone modifying complexes have been shown to be strongly associated with HCC including histone methyltransferases (SMYD3) \[[@b156]\], while a subunit of the TFTC/STAGA histone acetyltransferase complex has also been shown to be deregulated in HCC \[[@b158]\]. Finally, metastatic tumour antigen 1 MTA1 is another gene frequently overexpressed in HCC \[[@b159]\]. This protein has been shown to associate with various histone deacetylase complexes and further links aberrant chromatin remodelling activities to HCC \[[@b88]\].

### *In vitro* evidence for the use of HDi in liver cancer

We initially indicated that TSA might have use as a therapeutic modality in the treatment of HCC. Treatment of HCC cell lines with TSA was found to dramatically increase the expression of cyclin dependent kinase inhibitors, insulin-like growth factor binding protein-3 and transforming growth factor β (TGF-β), the overexpression of which are commonly associated with cell cycle arrest and/or apoptosis \[[@b162]\]. TSA and sodium butyrate were subsequently shown to decrease telomerase activity in hepatoma cell lines in addition to decreasing cellular proliferation \[[@b164]\]. TSA was shown to increase the activation of caspase-3 and promote apoptosis in hepatoma cells \[[@b165]\]. Using gene microarray profiling, we and others have examined the global gene expression changes for several HDi in hepatoma cells and identified many genes functionally altered following treatments of HDi \[[@b167]\]. Proteomic analysis of hepatoma cells treated with SAHA identified 55 differentially expressed proteins of which 34 were subsequently identified using mass spectrometry analysis \[[@b171]\]. We also demonstrated the efficacy of 4-phenylbutyrate in inducing apoptosis and tumour remission in hepatoma tumour xenografts \[[@b172]\]. Similar results were obtained for the HDi HA-But. This is a butyric acid coupled to hyaluronic acid via an esterification, and which has strong affinity for the CD44 membrane receptor. Most importantly, this compound had strong uptake into liver and was able to prevent hepatic metastases in a xenograft model *in vivo*\[[@b173]\]. Recently a new phenylbutyrate-derived HDi has been developed which shows strong antitumour activity in hepatoma models both in vitro (cell line) and in vivo (xenograft) even in xenografts with high tumour burden (\>500 mm^3^) \[[@b174]\].

Treating hepatoma cells with sodium butyrate researchers demonstrated that MMP-1 was being down-regulated, which correlated with a decreased ability to invade a matrigel assay \[[@b175]\]. Other HDi have also been shown to induce apoptosis in hepatoma cells including VPA and ITF2357 \[[@b176]\], while in onco-genically Ras-transformed rat liver epithelial (WB-Ras) cells, treatment of the cells with sodium butyrate caused the cells to undergo apoptosis and correlated with down-regulation of Ras-specific proteins \[[@b177]\]. Hepatoma cells pre-treated with VPA induce the expression of ligands that activate NK cell receptors and consequently mediate natural killer cell-mediated lysis of hepatoma cells \[[@b178]\].

### Combinatorial treatments involving HDi in hepatoma

Similarly to NSCLC, epigenetic targeting using a combination of HDi and demethylating agents have shown promise in an *in vivo* xenograft hepatoma model \[[@b179]\]. For instance, a triple combination of SAHA, irinotecan and 5-flurouracil (5-FU) led to a significant induction of apoptosis and cell death in hepatoma cells (92% after 72 hrs). Significantly, the double combination of irinotecan and 5-FU only led to a moderate increase in apoptosis and proliferation inhibition \[[@b180]\].

VPA has also been used to sensitize hepatoma cells to apoptosis in combination with the chemotherapy drug epirubicin \[[@b181]\]. Another study using VPA or another HDi (ITF2357) found that a combination of TRAIL and VPA or ITF2357 was able to selectively overcome the resistance of HCC cells toward TRAIL-mediated apoptosis \[[@b182]\]. Similarly to the effects seen for NSCLC cell lines, combinations of SAHA and bortezomib synergistically enhance apoptosis and cell death in hepatoma cells \[[@b183]\].

Potential role of histone deacetylase inhibitors in the treatment of diabetes
=============================================================================

Within diabetes pathogenesis, HATs and HDACs can be envisioned as affecting the expression of critical subsets of genes *via* three central mechanisms. At a basic level, the activities of these enzymes can affect chromatin at target genes themselves, and any alterations or disruptions of their activities could consequently lead to aberrant transcription of such genes. Alternatively, several proteins, which have been identified as the causative factors in monogenic autosomal dominant forms of type two diabetes (MODY, maturity onset diabetes of the young), have also been shown to associate with HATs/HDACs \[[@b184]\]. Indeed some of the mutations identified in these proteins result in loss of association with HATs/HDACs, or lead to a loss in HAT enzymatic activity \[[@b184]\]. There is an intimate network of associations between MODY proteins and consequently these mutant autosomal dominant conditions have aberrant regulation of critical downstream genes, which ultimately leads to the development of diabetes. Finally, the activities of HATs and HDACs are not limited to histones as they often directly modify transcription factors and regulatory proteins \[[@b7]\]. Alterations to the activities of HATs/HDACs may functionally result in the aberrant regulation of transcription of sets of target genes in diabetes pathogenesis.

Disease models, knockouts and assays
------------------------------------

Currently, no direct models exist to test the hypothesis that histone deacetylases are directly involved in diabetes pathogenesis. Some evidence has emerged for a role of HATs/HDACs in this disease comes from a mutant mouse model of a lysine acetyltransferase KAT3A. In this model, mice heterozygous for mutated KAT3A demonstrate increased insulin sensitivity and glucose tolerance even while demonstrating marked lipodystrophy of white adipose tissue \[[@b185]\]. Other indications that HATs/HDACs may be important therapeutic targets for diabetes come from studies on their roles in the TGF-β signalling pathway \[[@b184]\]. The TGF-β signalling pathway has well-established associations with HATs/HDACs and many of its downstream signalling processes including the signal transducer and activator of transcription (STAT) proteins have been linked to diabetes and links between TGF-β, STATs, HATs and HDACs well established \[[@b184]\].

Additional important evidence for the role of HATs and HDACs in diabetes comes from studies in both adipocyte and pancreas development, and due to space constraints the reader is directed to the following review on this topic \[[@b184]\]. Finally, a recent patent filed by Biovitrum AB has shown that in mouse models of insulin resistance, an interaction between insulin receptor substrate (IRS)-1 and HDAC2 occurs, which is absent in mouse models that have insulin sensitivity \[[@b186]\].

Pancreatic islet protection using histone deacetylase inhibitors
----------------------------------------------------------------

Several recent publications have demonstrated the ability of Hdi to protect pancreatic **p** cell apoptosis. In various diabetes models, nicotinamide has frequently been observed to both ameliorate and/or, accelerate the reversal of diabetes and prevent irreversible B-cell damage \[[@b187]\]. However, the European Nicotinamide Diabetes Intervention Trial (ENDIT) clinical trial assessing whether the pre-treatment with nicotinamide of non-diabetic individuals predisposed to the development of diabetes could prevent or delay clinical onset of diabetes was ineffective at the dose used \[[@b191]\], but did however reduce high secretion of IFN-gamma in high-risk individuals \[[@b192]\]. Insulin-secreting cells exposed long-term to either nicotinamide or sodium butyrate were found to have reduced viability and insulin sensitivity, yet enhanced insulin secretory responsiveness to a wide range of β cell stimulators \[[@b193]\]. Most recently, both TSA and SAHA were shown to prevent cytokine-induced toxicity in pancreatic β cells \[[@b194]\].

Additional *in vitro* evidence
------------------------------

Cell culture experimental systems are generating further evidence that Hdi may play important roles in targeting diabetes pathogenesis. A recent European patent has demonstrated that HDAC2 functionally associates with IRS-1, and that insulin sensitivity could be restored to a cell culture model of insulin resistance through the use of TSA \[[@b186]\]. Another example involves the restoration of mutant low-density lipoprotein receptor functionality using 4-phenylbutyrate \[[@b195]\]. As previously discussed the HDi 4-phenylbutyrate has been shown to have profound effects on relieving ER stress in a mouse model of diabetes, which resulted in improved glucose homeostasis \[[@b62]\].

Stem cells, HDACs and histone deacetylase inhibitors
----------------------------------------------------

A currently hotly pursued therapeutic avenue for diabetes centres on embryonic stem (ES) cell technology \[[@b196]\]. Evidence is emerging indicating that histone deacetylases may be an important consideration in the development of this technology. Indeed histone deacetylase activity has been shown to be required for ES cell differentiation \[[@b197]\]. The importance of HDAC inhibitors in differentiating ES cells in general has been reviewed recently elsewhere and the reader is directed to the following reviews \[[@b198]\].

Nicotinamide, a SIRT-specific inhibitor, was also used to differentiate ES cells into structures resembling pancreatic islets and which secreted insulin \[[@b200]\]. More recently, under appropriate culture conditions, Bone marrow stem cells (BMSC) cultured in the presence of the HDi TSA differentiated into islet-like clusters similar to the cells of the islets of the pancreas and capable of secreting insulin \[[@b201]\]. Using BMSCs derived from diabetic patients, similar results were obtained using Nicotinamide as one of the final steps in the differentiation process \[[@b202]\].

Two recent articles have utilized the HDi sodium butyrate to (*i*) stimulate early pancreatic development in ES cells \[[@b203]\] and (*ii*) generate Islet-like clusters from human ES cells grown under feeder-free conditions \[[@b204]\]. Finally, Scharfmann and colleagues have used various HDi to demonstrate that these enzymes are responsible for the timing and determination of pancreatic cell fate, by promoting the NGN3 pro-endocrine lineage leading to an increased pool of endocrine progenitors and modified endocrine sub-type lineage choices. Treatment of cells with TSA or sodium butyrate also enhanced the pool of β cells \[[@b205]\]. These results clearly demonstrate the potential of HDi in expanding pancreatic β cells from a stem cell population.

The potential role of histone deacetylase inhibitors in the treatment of neurodegenerative conditions
=====================================================================================================

Neuronal traits are modulated by HDAC/REST complexes
----------------------------------------------------

A study carried out in 1975 examined the acetylation status of histones in neuronal fractions \[[@b206]\]. Most recently it has now been demonstrated that HDACs play important roles in both neuron differentiation \[[@b207]\], expression of neuron-specific genes \[[@b208]\], and indeed regulate diverse cues such as maternal grooming \[[@b209]\], and addiction \[[@b210]\].

One of the best-established mechanisms in neurons involving HDACs concerns genes that are controlled by a specific protein repressor, neuron restrictive silencing transcription factor (NRSF, also known as REST) \[[@b211]\]. REST contains two distinct repressor domains, one located at the N-terminus and the other at the C-terminus of the protein and several distinct neuronal repressor complexes have now been isolated containing both REST and HDACs \[[@b211]\]. REST also associates with a novel protein called CoREST that interacts with HDACs to actively repress genes essential for neuronal phenotype \[[@b212]\]. The ATP-dependent remodelling complex SWI/SNF also plays a role in REST-mediated neuronal gene regulation, as it has recently emerged that CoREST recruits several SWI/SNF members, indicating that active chromatin remodelling is an element in REST-mediated repression \[[@b213]\]. CoREST complexes have also been shown to contain lysine methyltransferases, and recently an LSD1-CoREST-CtBP corepres-sor complex was shown to be required for late cell-lineage determination and differentiation during pituitary organogenesis \[[@b215]\].

Class II and Class III histone deacetylases also play pivotal roles in the proliferation and differentiation of neurons. SIRT1 has also been shown to protect primary cultures of cerebral granule neurons from FOXO induced cell death, while inactivation of a MEF2D/HDAC5 complex by depolarization-mediated calcium influx protects cerebellar granule neuron survival \[[@b211]\].

E2F, HDACs and neuronal survival mechanisms
-------------------------------------------

An essential feature for neuronal survival has also been linked to constitutive repression of E2F1 transcriptional activity through HDAC proteins. Elevated levels of E2f1 lead to neuronal apoptosis and enhanced immune cell proliferation, factors that could be deleterious in MS \[[@b211]\]. Using microarray analysis enhanced E2F pathway transcription was observed in the peripheral blood mononuclear cells from multiple sclerosis (MS) patients \[[@b216]\]. Subsequently, we demonstrated that HDAC inhibitors reduce levels of E2f class I proteins *in vivo*\[[@b217]\]. These observations may therefore help to explain why HDAC inhibitors, block immune cell proliferation \[[@b218]\] and enhance neuronal survival \[[@b219]\].

HDACs play important roles in stem cell neuronal differentiation
----------------------------------------------------------------

HDACs have also been shown to play important roles in neuronal stem cell (NSC) differentiation. Using 'dominant negative' stem cell lines expressing mutant, Flag-tagged HDACs with reduced enzymatic activity, Howard and colleagues found that mutant HDAC1 reduced differentiation to neurons by 50%\[[@b220]\]. The importance of HDACs in neuronal differentiation has also been demonstrated using HDAC inhibitors. In an *in vitro* study on the effects of the HDAC inhibitor TSA on the differentiation pattern of embryonic mouse NSCs during culture in a minimal, serum-free medium, it was found that under these conditions TSA treatment increased neuronal differentiation of the NSCs and decreased astrocyte differentiation \[[@b221]\]. In lineage-committed oligodendrocyte precursor cells inhibition of HDAC activity in these cells acted as a priming event in the induction of developmental plasticity \[[@b222]\]. A similar study examining the ability of oligodendrocyte progenitors to acquire the identity of myelin-expressing cells or choose alternative fates found that the activity of histone deacetylases was critical to these processes \[[@b223]\]. Emphasizing this finding, the transcription factor Yin Yang 1 (YY1) was shown to be a critical regulator of oligodendrocyte progenitor differentiation, acting as a lineage-specific repressor of transcriptional inhibitors of myelin gene expression (Tcf4 and Id4), through the recruitment of histone deacetylase-1 to their promoters during oligodendrocyte differentiation \[[@b224]\]. These studies underline the importance of HDACs in neuronal differentiation.

A direct role for histone deacetylases in the regulation of neural stem cell proliferation has been shown where the orphan nuclear receptor TLX, a critical regulator of stem cell proliferation was found to associate with HDAC3 and HDAC5. Inhibition of HDAC activity or knockdown of HDAC expression led to marked induction of TLX target gene expression and dramatically reduced neural stem cell proliferation \[[@b225]\]. REST is also critically involved with neural stem cell differentiation. Activation of REST is sufficient to cause neuronal differentiation \[[@b226]\]. REST complexes are able to both silence and repress neuronal genes in embryonic neural stem cells through the creation of chromatin environments that contain both repressive and active local epigenetic signatures \[[@b212]\].

It is now well established that several neuronal conditions can be linked to aberrant activities of lysine acetyltransferases and deacetylases including Huntington\'s disease, Rubinstein-Taybi syndrome, spinocerebellar ataxia type 1, spinocerebellar ataxia type 3, Alzheimer\'s, Parkinson\'s, spinal muscular atrophy, and amyotrophic lateral sclerosis \[[@b211]\].

Histone deacetylase inhibitors
==============================

SAHA has been the first directed HDi which has been FDA approved for the treatment of advanced primary cutaneous T-cell lymphoma \[[@b240]\]. In the following sections we will discuss the pharmacological and clinical data emerging from clinical trials using HDi ([Table 2](#tbl2){ref-type="table"}). Furthermore we will also discuss one of the issues emerging within the literature on whether the therapeutic efficiency of HDi is *via* transcriptional mechanisms, or through their ability to enhance chaperone activity.

###### 

Clinical parameters from clinical trials using HDi as single agents

  **Drug**                             **HDACs targeted**   **Phase**      **Method of delivery**                 **Dosage range**    **Adverse reactions**
  ------------------------------------ -------------------- -------------- -------------------------------------- ------------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Panobinostat (LBH589)                Class I, II          I              Oral                                   20 mg/m^2^          Grade 3 diarrhoea
  MGCD0103                             Class I              I              Oral                                   60 mg/m^2^          Fatigue, nausea, vomiting and diarrhoea
  Vorinostat                           Class I, II          FDA approved   Oral                                   200--600 mg/m^2^    Fatigue, dehydration, nausea and vomiting
  MS-275                               Class I              II             Oral                                   2--6 mg/m^2^        Hypophosphatemia, hyponatremia and hypoalbuminemia
  VPA                                  Class I              II             Oral                                   60 mg/kg/day        Grade 3, 4 neurocognitive impairment
  Phenylbutyrate                       Class I,II           I/II           Oral and intravenous (i.v.) infusion   60--360 mg/kg/day   Reversible neurocortical toxicity characterized by somnolence and confusion, short-term memory loss, sedation, confusion, nausea and vomiting
  Pivanex (AN-9)                                            II             i.v. infusion                          2.34 g/m^2^/day     Nausea, vomiting, hyperglycaemia, fatigue, diarrhoea and visual complaints
  CI-994                               Class I              I/II           Oral                                   4--6 mg/m^2^/day    Thrombocytopenia, fatigue, nausea, vomiting, diarrhoea, constipation and mucositis
  Belinostat (PXD101)                  Class I, II          I/II           i.v. infusion                          1000 mg/m^2^/day    Nausea, vomiting, fatigue and flushing atrial fibrillation
  Two cases of grade 4 renal failure                                                                                                  
  Romidepsin                           Class I              I/II           i.v. infusion                          10--26 mg/m^2^      Reversible cardiac dysrhythmias and non-specific ECG abnormalities thromocytopenia

1.  Initial pharmacological and clinical data

    Several studies have attempted to examine the pharmacological clearance of HDi. Initial studies on TSA showed that it undergoes intensive phase I biotransformation in rat hepatocytes, which has important consequences for its potential development as a drug, as this will lead to poor *in vivo* bioavailability of this drug \[[@b241]\]. These results were subsequently confirmed in a mouse model using intraperitoneal administration of TSA \[[@b242]\].

    In human liver microsomes, the metabolism of FK228 (romidepsin) has also been investigated. This compound gets metabolized rapidly into at least 10 metabolites at a Vmax 561.9 pmol/min./mg protein \[[@b243]\]. Hepatic clearance of apicidin has also been examined and an intrinsic Vmax of 927.0 ng/min/mg determined for human hepatic microsomes. In contrast another HDi MS-275 shows markedly little metabolism indicating that this is a minor of elimination for this drug \[[@b244]\].

2.  Current trials

    Several HDi have undergone both phase I/II clinical trials as anticancer agents \[[@b245]\], and as previously mentioned SAHA (vorinostat) has been FDA approved for the treatment of cutaneous T-cell lymphoma. As these trials proceed, greater understanding of the potential side effects and dose-limiting toxicities (DLTs) of these drugs begins to emerge. For the most part these first generation inhibitors have shown well-tolerated safety profiles.

SAHA (vorinostat)
-----------------

Several phase I clinical trials of vorinostat in solid and haematological tumours have been completed. In initial trials this drug was introduced intravenously and the most significant DLTs observed were leukopenia and thrombocytopenia \[[@b246]\]. An oral version of vorinostat was subsequently developed and phase I trials were found to have linear pharmacokinetics from 200 to 600 mg, with an apparent half-life ranging from 91 to 127 min. and 43% oral bioavailability \[[@b247]\]. Following the development of this oral form, a phase I trial was conducted in patients with mesothelioma. Similar toxicities to the original phase I trials were observed primarily fatigue, dehydration, nausea, and vomiting. Of four patients who completed greater than six cycles of therapy, two showed partial responses, which have led to a placebo-controlled, randomized phase III study of oral vorinostat for mesothelioma patients for whom treatment with pemetrexed has failed \[[@b248]\]. A phase II trial of vorinostat for refractory cutaneous T-cell lymphoma (CTCL) demonstrated both partial responses and ruritus relief, with limited toxicities of fatigue, thrombocytopenia, diarrhoea and nausea \[[@b249]\], and went on for further development. Following the completion of a single-arm, open-label, multi-centre pivotal trial and 11 other trials, clinical efficacy was assessed. Vorinostat showed activity in CTCL, and skin responses were a clinical benefit, and vorinostat was subsequently approved for treatment of cutaneous manifestations of CTCL \[[@b250]\]. A phase II trial of vorinostat has also been completed in patients with recurrent and/or metastatic head and neck cancer. In this trial, 12 patients received 400 mg once daily. Three patients had stable disease ranging from 9 to 26 weeks. Nine patients discontinued due to progressive disease, two withdrew consent, and one discontinued therapy for grade 3 anorexia. Overall, vorinostat was generally well tolerated but did not demonstrate efficacy as defined by tumour response \[[@b251]\]. In an open centre early phase II trial of oral vorinostat, patients with measurable, relapsed or refractory breast or non-small cell lung cancer who had received **\>**/**=** 1 prior therapy or colorectal cancer who had received **\>**/**=** 2 prior therapies were enrolled. Oral vorinostat (200, 300 or 400 mg) was taken twice daily for 14 days, followed by a 7-day rest until disease progression or intolerable toxicity was conducted, and the response rate, safety and tolerability were evaluated. Of the 16 patients recruited no DLTs were observed at 200 mg. Disease stabilization was observed in eight patients, but there were no confirmed responses \[[@b252]\].

Phenylbutyrate
--------------

Phenylbutyrate is another HDi for which several clinical trials have been carried out. When taken orally, the most common toxicities observed are grade 1--2 dyspepsia and fatigue \[[@b253]\]. Two phase I studies found that the DLTs included reversible neurocortical toxicity characterized by somnolence and confusion \[[@b254]\]. In a phase I study of sodium phenylbutyrate on patients with Huntington\'s disease, toxicities observed at the higher doses included vomiting, light-headedness, confusion and gait instability, but with no significant laboratory or electrocardiographic abnormalities \[[@b257]\].

Several trials testing phenylbutyrate on spinal muscular atrophy (SMA) have been carried out. The results of these studies found that the major side effect was a temporary stomach ache \[[@b258]\]. Unfortunately, in a randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy no significant improvements were observed \[[@b260]\]. However, it must be noted that in this trial, SMA patients were treated for only 13 weeks, and this may be too short a treatment period to identify any clinical benefit from PB. However, other trials continue to show further evidence that phenylbutyrate may have efficacy in the treatment of disease. In a phase I dose-escalation study in cystic fibrosis, a statistically significant induction of chloride transport was observed, with minimal adverse reactions \[[@b261]\].

Phenylbutyrate has also been used in phase I clinical trials for solid tumours. In this trial common adverse effects included grade I nausea/vomiting, fatigue and light-headedness, and the DLTs observed were short-term memory loss, sedation, confusion, nausea and vomiting. The maximum tolerated dose (MTD) was 300 mg/kg/day, and three of the twenty-one patients enrolled achieved stable disease \[[@b262]\]. A dose escalation study of oral phenylbutyrate has also been carried out in patients with recurrent malignant glioma. In agreement with the trials presented above, fatigue and somnolence were the worst toxicities observed. Of the twenty-three patients enrolled one patient had a complete response for 5 years \[[@b263]\].

Valproic acid
-------------

VPA has also entered clinical trials as a stand-alone agent in patients with advanced refractory cancer. Dose escalation was carried out in three-patient cohorts on twenty-six pre-treated patients. The MTD of infused drug was found to be 60 mg/kg/day, and the DLT was found to be grade 3 or 4 neurological side effects occurring in 8 out of 26 patients \[[@b264]\]. A phase II trial of VPA has also been completed in patients with castration-resistant prostate cancer. However, VPA was not found to be well tolerated by this cohort, and could not be administered reliably in order to achieve consistent levels or duration, and it was concluded that oral VPA is not recommended for prostate cancer \[[@b265]\].

In a phase I trial of continuous oral VPA for maintenance treatment in heavily pre-treated paediatric glioma patients, moderate tumour efficacy was observed \[[@b266]\]. VPA also shows potential in the treatment of neurodegenerative conditions. In a phase I trial of VPA on patients with human T-lymphotropic virus type 1 (HTLV-1), which is responsible for HTLV-associated myelopathy/tropical spastic paraparesis, clinical efficacy was observed. 16 patients were recruited and VPA was administrated orally at a maximal dose of 20 mg/kg/day. There was a significant drop in patient viral load from month 0 to month 3, and for the first time provides evidence that VPA leads to depletion of HTLV-1-infected cells in vivo \[[@b267]\]. The Project Cure SMA team has just completed the phase II CARNI-VAL clinical trial examining the effects of a combinatorial treatment of VPA and carnitine on SMA (<http://www.fsma.org>), but the results of this trial have yet to be disseminated to the greater scientific community.

AN-9
----

The drug Pivanex (AN-9) has completed both phase I and II clinical trials for advanced solid malignancies. No significant DLTs were observed in the phase I study and mild to moderate reactions included nausea, vomiting, hyperglycaemia, fatigue, diarrhoea and visual complaints \[[@b268]\]. During the phase II trial, similar tolerance was observed, with the worst effects including fatigue and hypokalemia \[[@b269]\].

CI-994
------

For the inhibitor CI-994 several phase I studies have been completed. The principal DLT observed for all trials was thrombocytopenia, but other side effects observed included nausea, vomiting diarrhoea and mucositis \[[@b270]\].

Romidepsin
----------

The HDi romidepsin has completed several phase I clinical trials on cancer and has also entered/completed phase II trials. In the phase I trials the major DLTs for this drug was again thromocytopenia. However, for this drug a significant increase in reversible cardiac dysrhythmias and non-specific ECG abnormalities were observed \[[@b274]\]. In a phase I dose-escalation trial of romidepsin in paediatric solid tumours romidepsin was administered as a 4-hr infusion weekly for three consecutive weeks every 28 days at dose levels of 10, 13, 17 and 22 mg/m^2^. Of the 24 patients enrolled, 18 could be assessed for toxicity. In agreement with the other phase I trials non-specific reversible ECG abnormalities were observed. Of the 18 patients three achieved long-term stable disease. For phase II trails the recommended dose was determined to be the recommended phase II dose in children with solid tumours is 17 mg/m^2^\[[@b277]\].

A second phase I trial in patients with acute myelogenous leukaemia or advanced myelodysplastic syndromes used 18 mg/m^2^ intravenous on days 1 and 5 every 3 weeks. The most common grade 3/4 toxicities were febrile neutropenia/infection, neutropenia/thrombocytopenia, nausea and asymptomatic hypophosphatemia, with no clinically significant cardiac toxicity. The best responses of 11 assessed patients was one complete remission (CR) in a patient with acute myeloid leukaemia (AML), stable disease in six patients. Notably however, histone H3 and H4 acetylation levels evaluated in five patients showed no consistent changes \[[@b278]\].

Two phase II trials of romidepsin have been completed. In a trial on twenty-nine patients with refractory metastatic renal cell cancer, the most common serious toxicities were fatigue, nausea, vomiting and anaemia. However, one patient developed a grade 3 atrial fibrillation, one patient developed tachycardia, and there was 1 sudden death. Within the study group itself two patients achieved an objective response, which was insufficient to bring this agent forward for further study in the treatment of renal cell cancer \[[@b279]\]. In a phase II trial on T-cell lymphoma, cardiac monitoring of 42 patients was carried out. The data obtained as part of this study indicate that the administration of romidepsin is not associated with myocardial damage or impaired cardiac function \[[@b280]\]. However, in a phase II study of romidepsin in neuroendocrine tumours, the study was terminated prematurely due to an unexpected high number of serious cardiac adverse events \[[@b281]\].

MS-275
------

MS-275 has just completed two phase I trials in solid tumours. The MTD of this drug was found to be 6 mg/m^2^, with a mean terminal half-life of 33.9 **±** 26.2 and a T(max) ranging from 0.5 to 24 hrs. Dose-limiting grade 3 toxicities were found to be reversible and included hypophosphatemia, hypoasthenia, hyponatremia and hypoalbuminemia \[[@b282]\] . In an earlier phase I study, the MTD was found to be 10 mg/m^2^ and DLTs were nausea, vomiting, anorexia and fatigue. In addition the half-life was found to be within the range 39--80 hrs \[[@b284]\]. In a phase I trial of MS-275 in patients with advanced acute leukaemias, the MTD was found to be 8 mg/m^2^ weekly for 4 weeks every 6 weeks. DLTs included infections and neurological toxicity manifesting as unsteady gait and somnolence. Other frequent toxicities observed were fatigue, anorexia, nausea, vomiting, hypoalbuminemia and hypocalcaemia \[[@b285]\]. In a trial to determine pharmacokinetic data for oral MS-275 in 64 adult patients receiving MS-275 orally (dose range, 2 to 12 mg/m^2^), no metabolites could be detected after incubation of MS-275 in human liver microsomes, suggesting that hepatic metabolism is a minor pathway of elimination, while the mean (±S.D.) apparent oral clearance of MS-275 was 38.5 **±** 18.7 l/hr \[[@b244]\].

Most recently a phase II trial of MS-275 has been completed in patients with metastatic melanoma. The primary study end-point was objective tumour response, but among 28 patients enrolled, no objective response was detected. Seven patients in showed disease stabilizations \[[@b286]\].

LBH589 (panobinostat)
---------------------

LBH5985 is currently undergoing an ongoing phase I, open-label, dose-escalation study in patients with solid tumours and non-Hodgkin\'s lymphoma. From this study, 10 patients with CTCLs were treated with oral panobinostat on a 28-day cycle. From this initial cohort of 10 patients complete responses were observed in 2 patients and partial responses in a further 4 individuals. The major DLT observed was a grade 3 diarrhoea at a dose of 30 mg \[[@b287]\].

MGC D0103
---------

This orally administered HDi has recently completed a phase I clinical trial in patients with leukaemia or myelodysplastic syndromes \[[@b288]\]. This was administered orally three times weekly without interruption, in a dose-escalation study of 20, 40 and 80 mg/m^2^. The MTD was determined to be 60 mg/m^2^, with DLTs of fatigue, nausea, vomiting, and diarrhoea observed at the higher doses. Of 29 patients enrolled, 3 achieved a complete bone marrow response (blasts **\<** or **=** 5%). Pharmacokinetic analyses indicated absorption of MGCD0103 within 1 hr and an elimination half-life in plasma of 9 (±2) hrs \[[@b288]\].

1.  PXD101 (Belinostat): Two phase I trial of belinostat have been completed, and several phase II clinical trials are in progress. In the first, a DLT study was carried out in 46 patients with confirmed advanced malignancy refractory to standard therapy or for whom no standard therapy existed. The MTD for Belinostat was determined to be 1000 mg/m^2^/days 1--5 in a 21-d cycle, and of the treated patients, 50% achieved stable disease \[[@b289]\]. The second trial was carried out in patients with advanced haematological neoplasia using the previously determined MTD. No complete or partial remissions were noted in these heavily pre-treated (median of four prior regimens) patients. However, five patients achieved some degree of disease stabilization \[[@b290]\].

2.  Combinatorial trials using Hdi.

The poor overall response of solid tumours to HDi as single agent therapies has resulted in several trials examining their potential as adjuvant therapies in combination with other drugs.

One HDi valproate, has completed a phase II trial examining its use as a combined epigenetic therapy with hydralazine to overcome chemotherapy resistance in refractory solid tumours. In this trial 17 patients were evaluable for toxicity and 15 for response. Twelve patients were found to respond with four showing a partial response and eight demonstrating stable disease (defined as neither sufficient tumour reduction to qualify for partial response nor sufficient increase to qualify for progressive disease) \[[@b291]\]. A phase I trial using a similar combination (hydralazine/valproate) plus neoadjuvant Doxorubicin Cyclophosphamide was carried out in patients with locally advanced breast cancer. 16 patients were included and received treatment. All were evaluated for clinical response and toxicity and 15 for pathological response. Treatment was well tolerated and the most common toxicity observed was patient drowsiness grades 1--2. Five (31%) patients had clinical response and eight (50%) had a partial response to give an overall response rate of 81%. There was a statistically significant decrease in both global 5-methylcytosine content and HDAC activity. The results obtained in this trial have resulted in the initiation of an ongoing randomized phase III study \[[@b292]\].

A pilot clinical trial involving phenylbutyrate and 5-azacytidine in patients with acute myeloid leukaemia or myelodysplastic syndrome has also been carried out. This combination regimen was well tolerated with common toxicities of injection site skin reaction (90% of the patients) from 5-azacytidine, and somnolence/fatigue from the sodium PB infusion (80% of the patients). Of the 10 patients in this trial, 5 patients (50%) were able to achieve a partial remission or stable disease, and 1 patient was able to proceed to allogeneic stem cell transplantation and was alive without evidence of disease 39 months later \[[@b293]\].

A phase I/II study of the combination of 5-aza-2'-deoxycytidine with VPA in patients with leukaemia was completed. In this study a group of 54 patients was recruited and treated with a fixed dose of decitabine (15 mg/m^2^ i.v. daily for 10 days) administered concomitantly with escalating doses of VPA orally for 10 days. The MTD of VPA was determined to be 50 mg/kg daily. Twelve (22%) patients had objective response, including 10 (19%) CRs and 2 (3%) CRs with incomplete platelet recovery (CRp). Remission duration was 7.2 months (range, 1.3--12.6+ months), while overall survival was 15.3 months (range, 4.6--20.2+ months) in responders \[[@b294]\].

Several trials involving VPA in combination with all-trans retinoic acid (ATRA) have been carried out. In one study on 26 patients with poor-risk AML VPA (5--10 mg/kg starting dose) and ATRA (45 mg/m^2^) were administered orally. Of 26 patients recruited, 19 completed at least 4 weeks of VPA/ATRA treatment. Seven patients were withdrawn prematurely because of rapidly progressive disease (*n***=** 3) or unacceptable neurological and cardiovascular toxicity (*n***=** 4). Three patients had partial responses \[[@b295]\]. A larger trial was carried out on 58 patients with advanced AML who were unfit for standard intensive chemotherapy. VPA was administered to reach serum concentrations between 50 and 100 g/ml, the therapeutic range used for VPA in anti-epileptic treatment. There were two different treatment schedules for ATRA, either 80 mg/m^2^ each day was given in two divided doses, days 1--7, every other week, or 15 mg/m^2^ was given daily, starting on day 4. Both drugs were administered orally. Treatment was continued as long as neither significant side effects nor disease progression occurred. Overall, treatment was well tolerated, but it was concluded that VPA had beneficial effects but was not sufficiently active to be useful as single-agent therapy for AML \[[@b296]\]. A larger phase II trial involving 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia, found that VPA was only clinically useful in low-risk myelodysplastic syndrome \[[@b297]\]. This was subsequently followed with a phase I/II study combining 5-azacitidine (5-AZA), VPA, and ATRA in patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome. In this trial 53 patients were treated. 5-AZA was administered subcutaneously at a fixed dose of 75 mg/m^2^ daily for 7 days. VPA was dose-escalated and given orally daily for 7 days concomitantly with 5-AZA. ATRA was given at 45 mg/m^2^ orally daily for 5 days, starting on day 3. The MTD of VPA in this combination was found to be 50 mg/kg daily for 7 days, and reversible neurotoxicity was the DLT Overall response rate to this treatment was 42%. The median remission duration was 26 weeks, and at the time of publication median survival had not yet been reached \[[@b298]\].

VPA has also undergone a phase I dose-escalation trial in combination with the topoisomerase II inhibitor epirubicin in advanced solid tumours. In this trial forty-eight patients were enrolled, and 44 received at least one cycle of therapy (increasing doses of VPA (days 1 through 3) followed by epirubicin (day 3) in 3-week cycles). DLTs observed were somnolence, confusion, and febrile neutropenia. The maximum-tolerated dose and recommended phase II dose identified was VPA 140 mg/kg/day for 48 hrs followed by epirubicin 100 mg/m^2^. In the treated patients partial responses were seen across different tumour types in nine patients (22%), and stable disease/minor responses were seen in 16 patients (39%), indicating that this combination may have potential in the treatment of solid tumours \[[@b299]\].

SAHA (vorinostat) has also completed a phase I trial in combination with Carboplatin and Paclitaxel for the treatment of advanced solid malignancies. Twenty-eight patients were enrolled into the study and separated into two arms for vorinostat treatment which was either administered orally once daily for two weeks or given twice daily for 1 week, every 3 weeks. Within each arm, the doses of vorinostat and paclitaxel were dose escalated in sequential cohorts of three patients. The DLT was determined to be 400 mg of vorinostat given once daily. Other non-DLTs included nausea, fatigue, diarrhoea and neuropathy. When patient response was evaluated, 10 of 19 (53%) of patients who had advanced chemo-naive non-small cell lung cancer (NSCLC) experienced a partial response and 4 had stable disease. In comparison, chemo-naive NSCLC patients just receiving carboplatin--paclitaxel generally achieve response rates of approximately (20--30%). These results indicate that vorinostat may enhance this therapy in NSCLC, and a phase II study randomizing advanced NSCLC patients to carboplatin-paclitaxel with either vorinostat or placebo is currently ongoing \[[@b300]\].

A phase I study combining cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer has been completed. In this study 5-flurouracil (FUra) was dose escalated (24-hr continuous intravenous infusion (2--2.3 g/m^2^), in combination with PB (120-hr continuous intravenous infusion at a fixed dose of 410 mg/kg/day × 5), and repeated weekly, in patients with advanced colorectal cancer. Nine patients were recruited and treated of which 8 could be assessed for toxicity. Weekly infusions of FUra followed by PB were fairly well tolerated with dose-dependent, reversible toxicities including somnolence, fatigue, confusion, hearing loss, triglyceridemia and hyperuricaema. Four patients completed eight weeks of treatment. Of these three achieved stable disease \[[@b301]\].

In a phase II randomized, double-blind, placebo-controlled, multi-centre study examining a combination of CI-994 and gemcitabine in patients with advanced pancreatic cancer. A total of 174 patients were recruited and received either a combination of CI-994/gemcitabine (CI-994 6 mg/m^2^/day days 1--21 plus gemcitabine 1000 mg/m^2^ days 1, 8 and 15 each 28-day cycle) or placebo/gemcitabine (placebo plus gemcitabine 1000 mg/m days 1, 8 and 15 of each 28-day cycle days 1--21). When the results were assessed, CI-994 offered no advantage over gemcitabine alone in the treatment of these patients, and indeed lowered their quality of life \[[@b302]\].

Caveats
=======

Intriguingly, HDi have been shown to be ineffective in causing apoptosis in non-small cell lung cancer cell line models. This was shown to be due to the transcriptional activation of NF-κB through the Akt pathway, with up-regulation of IL-8, Bcl-XL and MMP-9 transcripts \[[@b303]\]. A follow-up study using vorinostat (SAHA) has shown that this drug stimulates NF-κB transcription through a signalling cascade that involves activation of both the serine/threonine kinase Akt and the KAT3B acetyltransferase \[[@b304]\]. As such these studies provide evidence that HDi, such as SAHA, not only inhibit deacetylase activity but also stimulate active NF-κB transcription and cell survival through signalling pathways involving Akt and increased KAT3B acetyltransferase activity. This may have important implications in the use of histone deacetylases in the treatment of cancer as they may promote cancer cell survival, in contrast they may have important therapeutic implications in both diabetes and neurodegenerative disease as the may promote the survival of pancreatic β cells or protect neuronal cells.

Despite the evidence strongly suggesting that HDi may have an important therapeutic role in the treatment of obesity and diabetes nevertheless there are some caveats that temper this notion. One of the caveats concerns the use of VPA in the treatment of diabetes in that known side effects of this drug in patients are in fact, obesity and insulin resistance \[[@b305]\]. However, it must also be noted that in a study on the effects of HDAC inhibitors in adipocytes which included TSA and VPA it was found that VPA reduced leptin mRNA levels while TSA did not, suggesting that VPA therapy may be associated with altered leptin homeostasis contributing to weight gain *in vivo*, and therefore other HDAC inhibitors may not cause similar effects in relation to obesity and insulin resistance \[[@b312]\].

HDAC inhibitors have also been shown to up-regulate NF-κB driven pro-inflammatory cascades \[[@b313]\], albeit within a neural setting. Nevertheless this may also be true for multiple tissue types. In addition, HDi have also been shown to activate NF-κB, and to sustain the activation of NF-κB by delaying kBa mRNA resynthesis \[[@b315]\].

Within the clinical setting, other studies have shown the ineffectiveness of phenylbutyrate on relieving ER Stress in patients with α-1-antitrypsin deficiency \[[@b317]\].

Do HDAC inhibitors target genes or help chaperone activity as their primary response?
-------------------------------------------------------------------------------------

A plethora of studies have clearly shown that HDi can reactivate or alter gene expression. However, several studies now indicate that histone deacetylases and HDi may play important roles in regulating chaperone expression and function. This has important implications in conditions such as diabetes and obesity where aberrant misfolding of proteins can result in ER Stress. Indeed HDAC6 has been recognized as a leading regulator of cellular efforts to counteract the deleterious effects of misfolded protein accumulation \[[@b318]\]. Inhibition or depletion of HDAC6 leads to an induction of Hsp90 acetylation inhibiting its chaperone activity and eliciting cellular responses \[[@b146]\]. It must also be noted that HDAC6 is very resistant to various HDi including VPA and apicidin. The class I HDACs (HDACs 1--3) have been shown to associate with the ATP dependent chaperone Hsp70, and this association enhances deacetylase catalytic activity \[[@b327]\].

Emerging data clearly link the use of HDi in the relief of ER Stress in cell line models. Many of these studies have utilized the chemical 4-phenylbutyrate (PB). In a hepatocyte cell line model of oxidative stress induced ER Stress, treatment of cells with PB was found to alleviate the ER Stress in these cells \[[@b47]\]. General examples of the benefits of PB as a chemical chaperone have been described for relieving apoptosis and/or ER Stress in models of eye disease \[[@b59]\], rescue of defective trafficking of nephrin in kidney \[[@b328]\], rescue of protein trafficking in the lysosomal storage disorder Fabry disease \[[@b329]\], correction of autodominant hypoparathyroidism induced apoptosis \[[@b330]\] and relief of ER stress mediated programmed cell death in arabadopsis \[[@b331]\].

Other evidence for the potential of HDi influencing chaperone-like activities to relieve ER Stress have come from studies in neuroprotection lung, and liver disease. Within the neuronal setting, initial studies on mood stabilizing drugs such as VPA demonstrated increased expression of ER stress proteins in cerebral cortex, hippocampus, neuronal and glial cells \[[@b64]\]. Neuroprotective effects of these HDi have been observed to protect against ischaemia \[[@b55]\], malonate toxicity \[[@b336]\], rotenone \[[@b337]\], thapsigargin \[[@b339]\] and relieved ER Stress marker induction in a model of autosomal recessive juvenile Parkinsonism \[[@b58]\].

Studies on cystic fibrosis have shown that phenylbutyrate can restore CFTR trafficking and function \[[@b53]\], through the induction of Hsp90 \[[@b345]\]. Other lung conditions for which beneficial responses have been observed using HDi as chemical chaperones include respiratory distress syndrome \[[@b346]\], and emphysema \[[@b54]\].

Benefits accruing to the use of HDi as chemical chaperones in the liver have also been described. In one instance PB was used to protect liver cells from ER stress mediated apoptosis induced by liver ischaemia \[[@b56]\], enhances the cell surface expression and transport capacity of mutated bile salt export pumps \[[@b347]\], and reduces ER Stress induced formation of Mallory bodies in hepatocytes \[[@b47]\].

Increasing evidence is linking the activities of HDi to ER Stress in obesity. For instance, in a cell line model, phenylbutyrate has been shown to restore functionality to misfolded low-density lipoprotein receptors, and shuttle them to the cell surface. The authors concluded that their results indicate that phenylbutyrate did not just solely mediate this response by its ability to induce gene expression of proteins involved in intracellular transport, but could also mediate this effect *via* a direct chemical chaperone activity \[[@b195]\]. VPA was also shown to protect cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3 \[[@b348]\]. In a mouse model of type 2 diabetes, phenylbutyrate was found to reduce ER Stress and restore glucose homeostasis in the mutant mice \[[@b62]\]. This critical result underlines the potential importance of HDi as both regulators of gene expression and as chemical chaperones to dampen down inflammation and relieve ER Stress.

Final comments
==============

One critical element that needs to be addressed in future studies examining the efficacy of HDi in combinatorial trials should include studies to study the importance of timing for the scheduling of HDi within the protocol. *In vitro* studies using a combination of HDi and camptothecin, have shown that in NSCLC, the time of HDi addition is a critical determinant which can either cause cell protection or sensitization to camptothecin \[[@b349]\]. The development of tests that can predict the efficacy of HDi as an antitumour agent will also be an avenue that should be more thoroughly examined. It is interesting to note that a predictive model for HDi antitumour activity in non-small cell lung cancer has recently been developed through gene expression profiling, where a nine-gene classifier set has been found to have predictive value for determining drug sensitivity to HDi \[[@b350]\]. This exciting development raises the possibility of achieving individualized therapy for NSCLC patients, and potentially this could be expanded to individualized patient therapy for any disease.

Another area of critical importance will require the development of isoform-specific HDi, and area currently being actively pursued. The development of such inhibitors will allow better selectivity as tools for probing the biological functions of the isoforms, but also may function as better candidate therapeutic agents with fewer side effects \[[@b351]\]. For instance, a HDAC8-specific HDi PCI-3405 has been developed which has \>200-fold selectivity over the other HDAC isoforms, and induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukaemias, but not in other haematopoietic or solid tumour lines \[[@b353]\].

Finally, one avenue which has only recently begun to emerge concerns the effects of HDi on non-coding RNAs. This is especially important for miRNAs, which have been shown to be regulated via epigenetic mechanisms including histone acetylation and DNA CpG methylation \[[@b354]\].
